In India, the drug is not licensed for weight loss. but as anti-diabetic medication, warns Dr Chandrakant Lahariya.

Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) medications, researchers said.

Welcome to the healthier, happier world of 2030. Heart attacks and strokes are down 20%. A drop in food consumption has left ...

Powerful weight-loss drugs like Wegovy and Zepbound have driven nearly $1 trillion in market-capitalization gains, with most ...

No matter how effective doctors and patients say microdosing weight-loss drugs are, this form of medical experimentation may ...

However, in the face of a lawsuit brought by compounders ... Analysts have struggled to estimate the size of the compounded market for weight-loss drugs because their sale is not tracked in ...

Viking Therapeutics' weight loss drug VK2735 may challenge Novo Nordisk and Eli Lilly's dominance in the obesity drug space ...

The FDA became aware of the problem after a patient submitted a complaint to the regulator that a vial of semaglutide from ...

Wall Street analysts were impressed by data showing competitive rates of weight loss for Viking’s therapy, but shares in the ...

The drugmaker hopes to show CagriSema leads to at least 25% weight loss, without increased side effects. Its lead in a ...

However, in the face of a lawsuit brought by compounders ... Analysts have struggled to estimate the size of the compounded ...